Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Hepatocellular 6Neoplasms 3Neoplasm Metastasis 3Recurrence 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Nephrotic Syndrome 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Bladder Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Depression 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1Anxiety Disorders 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × Pharmaceutical Preparations × Clear all
NCT01544322 2015-06-18

ME-344-001

MEI Pharma, Inc.

Phase 1 Completed
24 enrolled

Neoplasm Metastasis, Recurrence

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

MEI Pharma, Inc.

Phase 1 Completed
18 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡